Skip to main content
Back to News
INFevo raises RMB 100M+ Pre-A to pair virtual-cell prediction with automated wet-lab validation
Funding
2 min read
CN

INFevo raises RMB 100M+ Pre-A to pair virtual-cell prediction with automated wet-lab validation

The AMW Read

New Chinese virtual-cell entrant with a large-for-sub-stage Pre-A (~$14M) adds a player to the bio-AI map, but the round is far below mega threshold and clinical or commercial validation is absent, keeping impact inside the sub-segment.
NoveltySignificance
Healthcare & Bio · Player Map
INFevo
INFevo

AI in Biotech / Drug Discovery

View Company Profile

INFevo raises RMB 100M+ Pre-A to pair virtual-cell prediction with automated wet-lab validation

Chinese AI startup INFevo has closed a Pre-A round of more than RMB 100 million (~$14M), drawing new investors Xinglian Capital, Prosperity7 Ventures, Huagai Capital, Huakong Fund, and DT Capital alongside follow-ons from Shunwei Capital, HSG, and Songhe Capital. The round lands five months after a June 2026 angel round in the tens of millions of yuan, and Xinglian calls it the largest single raise by a Chinese virtual-cell company above the RMB 100M mark. INFevo was incubated by XtalPi, which said in a July 16, 2026 announcement that its molecular-design and automated-synthesis capabilities complement INFevo's prediction technology.

The product is a virtual-cell model that forecasts how cells respond to drugs or genetic interventions before wet-lab work starts, paired with an automated experimental system that checks those predictions. The economics it targets are the costliest line in discovery: researcher time and wet-lab capacity burned on hypotheses likely to fail. Filtering weak candidates upstream positions the platform as R&D decision infrastructure for pharma and CROs, and a stable predict-validate loop would anchor long-term contracts plus proprietary experimental data. What is missing so far is proof: no disclosed numbers exist for clinical success uplift, pharma customer revenue, or commercial contracts, and cell-level prediction does not capture whole-organism biology.

For investors and builders, the next round will be priced on customer conversion, validation speed, and reproducibility rather than prediction accuracy. Watch whether the XtalPi relationship hardens into an integrated molecule-generation-to-validation pipeline, and whether Chinese bio-AI platforms combining state biotech support with private venture capital convert record early rounds into infrastructure that pharma R&D budgets actually pay for.

#BioAI #VirtualCell #DrugDiscovery #ChinaStartups #AIFunding

#INFevo#virtual-cell AI#drug discovery#China bio-AI funding#XtalPi

How This Connects

Based on Healthcare & Bio · Player Map

  1. 4d agoIsomorphic Labs raises $5 billion Series C for AI drug discoveryIsomorphic Labs
  2. 4d agoINFevo raises RMB 100M+ Pre-A to pair virtual-cell prediction with automated wet-lab validation · THIS ARTICLE
  3. 0mo agoPathos AI raises $237M to scale Foundry and advance four oncology assetsPathos
  4. 0mo agoWarp Sciences, founded by former OpenAI science lead Kevin Weil, raises $215M to automate drug-chemistry labsWarp Sciences

More news from INFevo

Stay updated with the latest news and announcements from INFevo.

View all INFevo news

Discover AI Startups

Explore 5,000+ AI companies with VC-grade analysis, funding data, and investment insights.

Explore Dashboard